Novel glucose-lowering medications and impact on diabetic retinopathy Oct. 13, 2025 Overview Show transcript Overview Andrew J. Barkmeier, M.D. discusses recent advances in glucose-lowering medications, including the systemic health benefits of GLP-1 RA medications in type 2 diabetes, potential risk factors for accelerated diabetic retinopathy progression and different categories of novel glucose-lowering medications for type 2 diabetes. Receive Mayo Clinic news in your inbox. Sign up Related ContentArticleChildren diagnosed with type 2 diabetes, increased risk of developing vision-threatening retinopathy VID-20599704 Medical Professionals Novel glucose-lowering medications and impact on diabetic retinopathy